Aldesleukin

Drug Profile

Aldesleukin

Alternative Names: Chiron IL-2; IL-2; IL-2 - Chiron; interleukin-2 - Chiron; Macrolin™; Proleukin; Recombinant IL-2; Recombinant-human-interleukin-2 - Chiron; T cell growth factor

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiron
  • Developer Hyup Jin Corporation; Ligand Pharmaceuticals; Novartis
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immunodeficiency disorders; Malignant melanoma; Renal cell carcinoma; Acute myeloid leukaemia; Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma; Renal cell carcinoma
  • Discontinued HIV-1 infections; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Aug 2017 Prometheus Laboratories terminates a phase II trial due to slow accrual for Malignant melanoma (Metastatic disease, Late-stage disease, Second-line or greater therapy) in USA (IV) (NCT02796352)
  • 01 Sep 2016 Prometheus Laboratories initiates a phase II trial for Malignant melanoma (Metastatic disease; Late-stage disease, Second-line or greater therapy) in USA (NCT02796352)
  • 15 Jun 2016 Prometheus Laboratories plans a phase II trial for Malignant melanoma (Metastatic disease; Late-stage disease, Second-line or greater therapy) in USA (NCT02796352)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top